Baseline | 6-month trial endpoint | 12-month follow-up | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome | Clinical cutoff score | n | Intervention | n | Control | n | Intervention | n | Control | n | Intervention | n | Control |
CBCL | ≥60 | 34 | 61.7 (6.5) | 33 | 61.0 (4.9) | 31 | 56.6 (7.0) | 28 | 57.1 (8.3) | 30 | 56.8 (8.3) | 26 | 55.5 (8.1) |
TRF | ≥60 | 31 | 53.7 (7.7) | 30 | 51.7 (8.0) | 31 | 54.7 (7.4) | 26 | 50.1 (9.3) | 25 | 54.4 (8.0) | 25 | 50.9 (8.4) |
ECBI intensity | ≥60 | 32 | 63.0 (6.7) | 32 | 59.9 (6.5) | 33 | 59.8 (7.3) | 30 | 58.2 (6.7) | 30 | 59.4 (7.7) | 26 | 58.3 (5.6) |
ECBI frequency | ≥60 | 32 | 59.3 (8.7) | 32 | 53.3 (9.5) | 33 | 53.0 (9.9) | 30 | 49.5 (9.1) | 30 | 52.2 (9.2) | 26 | 46.4 (6.1) |
PSI | n.a. | 33 | 5.3 (1.2) | 32 | 5.2 (0.9) | 33 | 4.7 (1.3) | 30 | 4.8 (1.2) | 29 | 5.0 (1.2) | 26 | 4.7 (1.1) |
CRPR restrictive | n.a. | 32 | 4.0 (0.6) | 32 | 3.9 (0.6) | 31 | 4.0 (0.5) | 30 | 4.0 (0.4) | 30 | 4.0 (0.6) | 26 | 4.0 (0.5) |
CRPR nurture | n.a. | 32 | 1.8 (0.4) | 32 | 1.8 (0.4) | 31 | 1.8 (0.3) | 30 | 1.8 (0.4) | 30 | 1.8 (0.3) | 26 | 1.8 (0.3) |
VCS | n.a. | 32 | 50.4 (5.3) | 32 | 49.9 (6.7) | 33 | 52.7 (4.8) | 30 | 51.0 (6.7) | 30 | 51.8 (4.9) | 26 | 53.0 (5.8) |